In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma (CANF – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $1.24.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 27.9% and a 38.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Aridis Pharmaceuticals.
Can-Fite BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, implying a 455.6% upside from current levels. In a report issued on March 25, Dawson James also maintained a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn’s disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.
Read More on CANF:
- Formfactor (FORM) Gets a Buy Rating from Needham
- H.C. Wainwright Reiterates a Buy Rating on Solitario Exploration & Royalty (XPL)
- H.C. Wainwright Sticks to Their Buy Rating for Sandstorm Gold (SAND)
- Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL) and Atreca (BCEL)
- Stock Futures in Red amid Fresh Hints to Tighten Monetary Policy